{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:27:21Z","timestamp":1793251641436,"version":"4.5.0"},"reference-count":88,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8,1]]},"abstract":"<jats:p>Despite recent advances in the management of phenylketonuria and hyperphenylalaninemia, important questions on the management of this disorder remain unanswered. Consensus exists on the need for neonatal screening and early treatment, yet disagreement persists over threshold levels of blood phenylalanine for starting treatment, target blood phenylalanine levels, and the management of older patient groups. The mainstay of treatment is a phenylalanine-restricted diet, but its application varies between and within countries. Beyond diet treatment, there is a lack of consensus on the use of newer treatments such as tetrahydrobiopterin. Although neonatal screening and early treatment has meant that most well-treated children grow up with near-normal IQ scores, the effect of relaxing metabolic control on cognitive and executive function later in life is still not fully understood. Although it is clear from the available literature that the active control of blood phenylalanine levels is of vital importance, there are other treatment-related factors that affect outcome. A uniform and firmly evidence-based approach to the management of phenylketonuria is required.<\/jats:p>","DOI":"10.1542\/peds.2009-3584","type":"journal-article","created":{"date-parts":[[2010,7,13]],"date-time":"2010-07-13T00:59:43Z","timestamp":1278982783000},"page":"333-341","source":"Crossref","is-referenced-by-count":67,"title":["Challenges and Pitfalls in the Management of Phenylketonuria"],"prefix":"10.1542","volume":"126","author":[{"given":"Fran\u00e7ois","family":"Feillet","sequence":"first","affiliation":[{"name":"Service de M\u00e9decine Infantile 1, Centre de R\u00e9f\u00e9rence des Maladies H\u00e9r\u00e9ditaires du M\u00e9tabolisme, INSERM U 954, CHU Brabois Enfants, Vandoeuvre les Nancy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francjan J.","family":"van Spronsen","sequence":"additional","affiliation":[{"name":"Beatrix Children's Hospital, University Medical Center of Groningen, University of Groningen, Groningen, Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Dietetics Department, The Children's Hospital, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich K.","family":"Trefz","sequence":"additional","affiliation":[{"name":"Klinik fur Kinder und Jugendmedizin Reutlingen, Reutlingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcbeccel","family":"Demirkol","sequence":"additional","affiliation":[{"name":"Division of Nutrition and Metabolism, Istanbul Faculty of Medicine, Istanbul University, Children's Hospital, Istanbul, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Giovannini","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, San Paolo Hospital, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"B\u00e9langer-Quintana","sequence":"additional","affiliation":[{"name":"Unidad Enfermendades Metabolicas, Servicio de Pediatria, Hospital Ramon y Cajal, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Blau","sequence":"additional","affiliation":[{"name":"Division of Clinical Chemistry and Biochemistry, University Children's Hospital, Z\u00fcrich, Switzerland; and"},{"name":"Z\u00fcrich Center for Integrative Human Physiology, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2010,8,1]]},"reference":[{"key":"2021120820151848300_B1","unstructured":"National Center for Biotechnology Information. Online Mendelian Inheritance in Man database: #261600\u2014phenylketonuria; PKU. Available at: www.ncbi.nlm.nih.gov\/entrez\/dispomim.cgi?id=261600. Accessed December 30, 2009"},{"issue":"1","key":"2021120820151848300_B2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000252834","article-title":"Evaluation of somatic development in adult patients with previously undiagnosed and\/or untreated phenylketonuria","volume":"19","author":"Mazur","year":"2010","journal-title":"Med Princ Pract"},{"issue":"2","key":"2021120820151848300_B3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1542\/peds.20.2.290","article-title":"The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria)","volume":"20","author":"Paine","year":"1957","journal-title":"Pediatrics"},{"issue":"6790","key":"2021120820151848300_B4","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(53)90473-5","article-title":"Influence of phenylalanine intake on phenylketonuria","volume":"265","author":"Bickel","year":"1953","journal-title":"Lancet"},{"issue":"4","key":"2021120820151848300_B5","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1542\/peds.108.4.972","article-title":"National Institutes of Health Consensus Development Conference statement: phenylketonuria\u2014screening and management, October 16\u201318, 2000","volume":"108","author":"National Institutes of Health Consensus Development Panel","year":"2001","journal-title":"Pediatrics"},{"issue":"3","key":"2021120820151848300_B6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/adc.68.3.426","article-title":"Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria","volume":"68","year":"1993","journal-title":"Arch Dis Child"},{"issue":"2","key":"2021120820151848300_B7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ymgme.2009.09.005","article-title":"Management of phenylketonuria in Europe: survey results from 19 countries","volume":"99","author":"Blau","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2021120820151848300_B8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clnu.2009.03.004","article-title":"Dietary management practices in phenylketonuria across European centres","volume":"28","author":"Ahring","year":"2009","journal-title":"Clin Nutr"},{"key":"2021120820151848300_B9","first-page":"92","article-title":"Classification of PKU","volume-title":"Advances in Phenylketonuria and Tetrahydrobiopterin","author":"Marsden","year":"2006"},{"key":"2021120820151848300_B10","first-page":"180","article-title":"Treatment of phenylketonuria variants: European recommendations","volume-title":"PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin","author":"Lindner","year":"2006"},{"key":"2021120820151848300_B11","first-page":"89","article-title":"Disorders of phenylalanine and tetrahydrobiopterin metabolism","volume-title":"Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases","author":"Blau","year":"2002","edition":"2nd ed."},{"key":"2021120820151848300_B12","unstructured":"National Society for PKU. Management of PKU. Available at: www.nspku.org\/Documents\/Management%20of%20PKU.pdf.\u2008Accessed December 30, 2009"},{"key":"2021120820151848300_B13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/3-540-28962-3_3","article-title":"Disorders of phenylalanine and tetrahydrobiopterin","volume-title":"Physician's Guide to the Treatment and Follow-up of Metabolic Diseases","author":"Blau","year":"2006"},{"issue":"6","key":"2021120820151848300_B14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/301638","article-title":"Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations","volume":"61","author":"Kayaalp","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2021120820151848300_B15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/humu.20637","article-title":"Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency","volume":"29","author":"Zurfl\u00fch","year":"2008","journal-title":"Hum Mutat"},{"issue":"4","key":"2021120820151848300_B16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1096-7192(02)00171-3","article-title":"High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002","volume":"77","author":"Bernegger","year":"2002","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2021120820151848300_B17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ymgme.2009.01.002","article-title":"Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria","volume":"96","author":"Blau","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2021120820151848300_B18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jpeds.2007.02.017","article-title":"Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria","volume":"150","author":"Fiege","year":"2007","journal-title":"J Pediatr"},{"issue":"3","key":"2021120820151848300_B19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-3476(99)70138-1","article-title":"Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency","volume":"135","author":"Kure","year":"1999","journal-title":"J Pediatr"},{"issue":"3","key":"2021120820151848300_B20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ymgme.2009.03.009","article-title":"Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency","volume":"97","author":"Karaci\u0107","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"7","key":"2021120820151848300_B21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1017\/S0012162205000861","article-title":"Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population","volume":"47","author":"Gassi\u00f3","year":"2005","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"2021120820151848300_B22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10545-007-0552-8","article-title":"Phenylketonuria: dietary and therapeutic challenges","volume":"30","author":"Giovannini","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2021120820151848300_B23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/adc.65.5.472","article-title":"Intelligence and quality of dietary treatment in phenylketonuria","volume":"65","author":"Smith","year":"1990","journal-title":"Arch Dis Child"},{"issue":"2","key":"2021120820151848300_B24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11065-007-9021-2","article-title":"Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU","volume":"17","author":"Moyle","year":"2007","journal-title":"Neuropsychol Rev"},{"issue":"1\u20132","key":"2021120820151848300_B25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2007.05.006","article-title":"Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis","volume":"92","author":"Waisbren","year":"2007","journal-title":"Mol Genet Metab"},{"key":"2021120820151848300_B26","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/PL00014388","article-title":"Development of intelligence in early treated phenylketonuria","volume":"159","author":"Burgard","year":"2000","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2021120820151848300_B27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/B:BOLI.0000028781.94251.1f","article-title":"Executive function impairment in early-treated PKU subjects with normal mental development","volume":"27","author":"Leuzzi","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"2021120820151848300_B28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1651-2227.1994.tb13464.x","article-title":"Review of neuropsychological functioning in treated phenylketonuria: an information processing approach","volume":"407","author":"Waisbren","year":"1994","journal-title":"Acta Paediatr Suppl"},{"issue":"1","key":"2021120820151848300_B29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1399-0004.2007.00816.x","article-title":"Executive functioning in children and adolescents with phenylketonuria","volume":"72","author":"VanZutphen","year":"2007","journal-title":"Clin Genet"},{"issue":"3","key":"2021120820151848300_B30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.neubiorev.2008.11.001","article-title":"Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis","volume":"33","author":"Albrecht","year":"2009","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"2021120820151848300_B31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0028-3932(01)00078-1","article-title":"Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations","volume":"40","author":"Huijbregts","year":"2002","journal-title":"Neuropsychologia"},{"issue":"1","key":"2021120820151848300_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S135561770102001X","article-title":"Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria","volume":"8","author":"White","year":"2002","journal-title":"J Int Neuropsychol Soc"},{"issue":"6","key":"2021120820151848300_B33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1023\/A:1026239921561","article-title":"Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression","volume":"31","author":"Antshel","year":"2003","journal-title":"J Abnorm Child Psychol"},{"issue":"3","key":"2021120820151848300_B34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1542\/peds.99.3.345","article-title":"Psychiatric disorders in adult patients with early-treated phenylketonuria","volume":"99","author":"Pietz","year":"1997","journal-title":"Pediatrics"},{"issue":"2","key":"2021120820151848300_B35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1022999712639","article-title":"Autism and phenylketonuria","volume":"33","author":"Baieli","year":"2003","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"2021120820151848300_B36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/BF01799946","article-title":"Agoraphobia in phenylketonuria","volume":"14","author":"Waisbren","year":"1991","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2021120820151848300_B37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/BF00711596","article-title":"Personality disorder in young women with treated phenylketonuria","volume":"17","author":"Waisbren","year":"1994","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"2021120820151848300_B38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/BF01957759","article-title":"Psychological and social findings in adolescents with phenylketonuria","volume":"151","author":"Weglage","year":"1992","journal-title":"Eur J Pediatr"},{"issue":"8","key":"2021120820151848300_B39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1023\/A:1005482732411","article-title":"Benefits of normalizing plasma phenylalanine: impact on behaviour and health\u2014a case report","volume":"21","author":"Williams","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"2021120820151848300_B40","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1007\/PL00014370","article-title":"The neurochemistry of phenylketonuria","volume":"159","author":"Surtees","year":"2000","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2021120820151848300_B41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1148\/radiology.177.2.2217781","article-title":"Phenylketonuria: MR imaging of the brain with clinical correlation","volume":"177","author":"Pearsen","year":"1990","journal-title":"Radiology"},{"key":"2021120820151848300_B42","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ymgme.2005.06.014","article-title":"Impaired glutamatergic synaptic transmission in the PKU brain","volume":"86","author":"Martynyuk","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2021120820151848300_B43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/1097-4547(20000901)61:5<549::AID-JNR10>3.0.CO;2-0","article-title":"Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and forebrain pathology in the PKU mouse?","volume":"61","author":"Shefer","year":"2000","journal-title":"J Neurosci Res"},{"issue":"4 pt 1","key":"2021120820151848300_B44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1203\/01.pdr.0000203091.45988.8d","article-title":"Phenylalanine reduces synaptic density in mixed cortical cultures from mice","volume":"59","author":"H\u00f6rster","year":"2006","journal-title":"Pediatr Res"},{"key":"2021120820151848300_B45","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1007\/PL00014257","article-title":"Neurotransmitter positron emission tomographic-studies in adults with phenylketonuria, a pilot study","volume":"155","author":"Paans","year":"1996","journal-title":"Eur J Pediatr"},{"issue":"4","key":"2021120820151848300_B46","doi-asserted-by":"crossref","first-page":"i","DOI":"10.2307\/1166208","article-title":"Prefrontal cortex cognitive deficits in children treated early and continuously for PKU","volume":"62","author":"Diamond","year":"1997","journal-title":"Monogr Soc Res Child Dev"},{"issue":"2","key":"2021120820151848300_B47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1098-2779(1999)5:2<104::AID-MRDD2>3.0.CO;2-7","article-title":"Pathophysiology of phenylketonuria","volume":"5","author":"Dyer","year":"1999","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"6","key":"2021120820151848300_B48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0149-7634(02)00040-4","article-title":"The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory","volume":"26","author":"Huijbregts","year":"2002","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"2021120820151848300_B49","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymgme.2005.06.010","article-title":"Cerebral glucose metabolism in adults with early treated classic phenylketonuria","volume":"87","author":"Wasserstein","year":"2006","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2021120820151848300_B50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ymgme.2008.12.019","article-title":"Phenylketonuria: high plasma phenylalanine decreases cerebral protein synthesis","volume":"96","author":"Hoeksma","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2021120820151848300_B51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1067\/mpd.2001.117576","article-title":"Tyrosine supplementation in phenylketonuria: diurnal blood tyrosine levels and presumptive brain influx of tyrosine and other large neutral amino acids","volume":"139","author":"Kalsner","year":"2001","journal-title":"J Pediatr"},{"issue":"1\u20132","key":"2021120820151848300_B52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ymgme.2008.06.014","article-title":"Stability of blood phenylalanine levels and IQ in children with phenylketonuria","volume":"95","author":"Anastasoaie","year":"2008","journal-title":"Mol Genet Metab"},{"key":"2021120820151848300_B53","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/PL00014222","article-title":"Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria","volume":"155","author":"Burgard","year":"1996","journal-title":"Eur J Pediatr"},{"key":"2021120820151848300_B54","first-page":"299","article-title":"Recommendations for brain phenylalanine levels in adult individuals with phenylketonuria [abstract]","volume":"8","author":"Moats","year":"2000","journal-title":"Proc Int Soc Magn Reson Med Sci Meet Exhib Int Soc Magn Reson Med Sci Meet Exhib"},{"issue":"11","key":"2021120820151848300_B55","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/00004647-199811000-00004","article-title":"Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria","volume":"18","author":"M\u00f6ller","year":"1998","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"2021120820151848300_B56","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00004647-200103000-00011","article-title":"Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria","volume":"21","author":"Rupp","year":"2001","journal-title":"J Cereb Blood Flow Metab"},{"key":"2021120820151848300_B57","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.ymgme.2005.07.031","article-title":"Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc\/LAT1 complex","volume":"86","author":"M\u00f8ller","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2021120820151848300_B58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2105\/AJPH.74.5.501","article-title":"Diet policies of PKU clinics in the United States","volume":"74","author":"Schuett","year":"1984","journal-title":"Am J Public Health"},{"issue":"4","key":"2021120820151848300_B59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02312549","article-title":"Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome","volume":"3","author":"Waisbren","year":"1980","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"2021120820151848300_B60","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10545-008-0918-6","article-title":"The truth of treating patients with phenylketonuria after childhood: the need for a new guideline","volume":"31","author":"van Spronsen","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2021120820151848300_B61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10545-008-0966-y","article-title":"PKU: what is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders","volume":"32","author":"van Spronsen","year":"2009","journal-title":"J Inherit Metab Dis"},{"issue":"21","key":"2021120820151848300_B62","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM198311243092101","article-title":"Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus","volume":"309","author":"Levy","year":"1983","journal-title":"N Engl J Med"},{"issue":"6 pt 2","key":"2021120820151848300_B63","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1542\/peds.112.S4.1537","article-title":"Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study","volume":"112","author":"Widaman","year":"2003","journal-title":"Pediatrics"},{"issue":"3","key":"2021120820151848300_B64","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajcn\/88.3.700","article-title":"Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine","volume":"88","author":"Maillot","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"2021120820151848300_B65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ajcn\/67.3.473","article-title":"Tyrosine supplementation in the treatment of maternal phenylketonuria","volume":"67","author":"Rohr","year":"1998","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2021120820151848300_B66","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004731.pub3","article-title":"Protein substitute for children and adults with phenylketonuria","author":"Yi","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021120820151848300_B67","doi-asserted-by":"crossref","first-page":"996S","DOI":"10.1093\/jn\/134.4.996S","article-title":"Manufacture and use of dairy protein fractions","volume":"134","author":"Etzel","year":"2004","journal-title":"J Nutr"},{"issue":"2","key":"2021120820151848300_B68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jn\/138.2.316","article-title":"Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria","volume":"138","author":"Ney","year":"2008","journal-title":"J Nutr"},{"issue":"4","key":"2021120820151848300_B69","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3945\/ajcn.2008.27280","article-title":"Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids","volume":"89","author":"van Calcar","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2021120820151848300_B70","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1111\/j.1750-3841.2009.01134.x","article-title":"Purification and use of glycomacropeptide for nutritional management of phenylketonuria","volume":"74","author":"Laclair","year":"2009","journal-title":"J Food Sci"},{"issue":"4","key":"2021120820151848300_B71","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10545-009-1132-x","article-title":"Large neutral amino acids supplementation in phenylketonuric patients","volume":"32","author":"Rocha","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"2021120820151848300_B72","unstructured":"Sapropterin dihydrochloride (Kuvan). European summary of product characteristics. Available at: www.emc.medicines.org.uk\/medicine\/21362\/SPC\/Kuvan+100+mg+soluble+tablets.\u2008Accessed December 30, 2009"},{"issue":"9586","key":"2021120820151848300_B73","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"2021120820151848300_B74","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2021120820151848300_B75","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J Pediatr"},{"issue":"9","key":"2021120820151848300_B76","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.earlhumdev.2008.01.003","article-title":"Evaluation of neonatal BH4 loading test in neonates screened for hyperphenylalaninemia","volume":"84","author":"Feillet","year":"2008","journal-title":"Early Hum Dev"},{"key":"2021120820151848300_B77","unstructured":"BioMarin Pharmaceutical\u2008Inc . Results from phase 1 clinical study of PEG-PAL in PKU and update on phase 2 clinical study [press release]. Available at: http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=106657&p=irol-newsArticle&ID=1297622&highlight=.\u2008Accessed November 18, 2009"},{"issue":"2","key":"2021120820151848300_B78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1399-0004.2008.01027.x","article-title":"Progress toward cell-directed therapy for phenylketonuria","volume":"74","author":"Harding","year":"2008","journal-title":"Clin Genet"},{"issue":"4","key":"2021120820151848300_B79","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/mt.2008.17","article-title":"Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system","volume":"16","author":"Ding","year":"2008","journal-title":"Mol Ther"},{"issue":"2","key":"2021120820151848300_B80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00125817-200203000-00006","article-title":"Barriers to successful dietary control among pregnant women with phenylketonuria","volume":"4","author":"Brown","year":"2002","journal-title":"Genet Med"},{"issue":"1","key":"2021120820151848300_B81","first-page":"60","article-title":"Insurance coverage of special foods needed in the treatment of phenylketonuria","volume":"108","author":"Millner","year":"1993","journal-title":"Public Health Rep"},{"issue":"6","key":"2021120820151848300_B82","doi-asserted-by":"crossref","DOI":"10.1542\/peds.104.6.e68","article-title":"Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors","volume":"104","author":"Wappner","year":"1999","journal-title":"Pediatrics"},{"issue":"6","key":"2021120820151848300_B83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1023\/A:1021234730512","article-title":"Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria","volume":"25","author":"Weglage","year":"2002","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2021120820151848300_B84","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1203\/00006450-200104000-00015","article-title":"Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia","volume":"49","author":"Weglage","year":"2001","journal-title":"Pediatr Res"},{"issue":"4","key":"2021120820151848300_B85","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ajcn\/72.4.976","article-title":"Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients","volume":"72","author":"van Bakel","year":"2000","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"2021120820151848300_B86","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clinbiochem.2003.10.017","article-title":"A longitudinal study of antioxidant status in phenylketonuric patients","volume":"37","author":"Artuch","year":"2004","journal-title":"Clin Biochem"},{"issue":"4","key":"2021120820151848300_B87","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11011-006-9035-0","article-title":"Investigation of oxidative stress parameters in treated phenylketonuric patients","volume":"21","author":"Sitta","year":"2006","journal-title":"Metab Brain Dis"},{"issue":"1\u20132","key":"2021120820151848300_B88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mrgentox.2009.07.013","article-title":"Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients","volume":"679","author":"Sitta","year":"2009","journal-title":"Mutat Res"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/126\/2\/333\/1176438\/zpe00810000333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/126\/2\/333\/1176438\/zpe00810000333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T02:00:26Z","timestamp":1685671226000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/126\/2\/333\/68668\/Challenges-and-Pitfalls-in-the-Management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,1]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,8,1]]},"published-print":{"date-parts":[[2010,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2009-3584","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,1]]}}}